What you can do: Avoid buying cheap, unverified peptide powders from unregulated social media links or random websites
Prescribers initiating BPC-157 in patients with Child-Pugh A or B hepatic impairment should document: (1) the clinical rationale for peptide therapy, (2) the absence of an FDA-approved alternative for the target condition, (3) baseline hepatic function with planned monitoring intervals, and (4) the patient's informed consent acknowledging the investigational nature of the therapy and the specific evidence limitations in their population
I genuinely look at peptides as an investment category rather than a personal consumption category, she says
Available from: Chen L, Chetkovich DM, Petralia RS, Sweeney NT, Kawasaki Y, Wenthold RJ, et al
No matter what your health and weight loss goals are, we are here to guide you back to the healthiest version of you
A diagnosis needs to exist in your chart as an actual ICD-10 code